02_CD
GlaxoSmithKline_NN
Financial_NN
summary_NN
2001_CD
2002_CD
restated_VBN
Increase_VPRT
Statutory_JJ
results_NN
m_VPRT [BEMA]
m_JJ
%_NN
CER_CD
%_NN
Sales_NN
21,212_CD
20,489_CD
4_CD
7_CD
Trading_GER
profit_NN
5,662_CD
4,697_CD
21_CD
26_CD
profit_NN
before_IN
taxation_NOMZ
5,506_CD
4,517_CD
22_CD
28_CD
Earnings_GER
Net_JJ
income_NN
3,915_CD
3,053_CD
28_CD
35_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
66.2_CD
p_NN
50.3_CD
p_NN
32_CD
38_CD
Dividends_NN
per_PIN
share_NN
40.0_CD
p_VPRT
39.0_CD
p_JJ
Merger_NN
,_,
restructuring_GER
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
Trading_GER
profit_NN
1,032_CD
1,356_CD
profit_NN
before_IN
taxation_NOMZ
1,011_CD
1,652_CD
Earnings_GER
Net_JJ
income_NN
712_CD
1,330_CD
Business_NOMZ
performance_NN
Sales_NN
21,212_CD
20,489_CD
4_CD
7_CD
Trading_GER
profit_NN
6,694_CD
6,053_CD
11_CD
15_CD
profit_NN
before_IN
taxation_NOMZ
6,517_CD
6,169_CD
6_CD
11_CD
Adjusted_VBN
earnings_GER
Net_JJ
income_NN
4,627_CD
4,383_CD
6_CD
11_CD
Adjusted_VBN
earnings_GER
per_PIN
share_NN
78.3_CD
p_NN
72.3_CD
p_NN
8_CD
13_CD
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
is_VPRT [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_CC
the_DT
disposal_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
non-recurring_JJ
items_NN
provides_VPRT
a_DT
better_JJ
comparison_NN
of_PIN
business_NOMZ
performance_NN
for_PIN
the_DT
periods_NN
presented_VBN
._.
Statutory_JJ
results_NN
include_VPRT
these_DEMO
non-recurring_JJ
items_NN
._.
This_DEMO
information_NOMZ
is_VPRT [PASS]
provided_VBN
as_IN
a_DT
supplement_NOMZ
to_PIN
that_DEMP
included_VBN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
on_PIN
pages_NN
76_CD
and_CC
77_CD
prepared_JJ
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
The_DT
Group_NN
,_,
as_IN
a_DT
multinational_JJ
business_NOMZ
,_,
operates_VPRT
in_PIN
many_QUAN
countries_NN
and_CC
earns_VPRT
revenues_NN
and_CC
incurs_VPRT
costs_NN
in_PIN
many_QUAN
currencies_NN
._.
The_DT
results_NN
of_PIN
the_DT
Group_NN
,_,
as_IN
reported_VBN [PUBV]
in_PIN
sterling_GER
,_,
are_VPRT [SPAU] [BYPA]
therefore_CONJ
affected_VBN
by_PIN
movements_NOMZ
in_PIN
exchange_NN
rates_NN
between_PIN
sterling_GER
and_CC
overseas_PLACE
currencies_NN
._.
The_DT
Group_NN
uses_VPRT
the_DT
average_JJ
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
during_PIN
the_DT
year_NN
to_TO
translate_VB
the_DT
results_NN
of_PIN
overseas_PLACE
companies_NN
into_PIN
sterling_GER
._.
The_DT
currencies_NN
which_WDT
most_EMPH
inuence_JJ
these_DEMO
translations_NOMZ
are_VPRT [BEMA]
the_DT
US_FPP1
dollar_NN
,_,
the_DT
Euro_NN
and_CC
the_DT
Japanese_JJ
Yen_NN
._.
During_PIN
2002_CD
average_JJ
sterling_JJ
exchange_NN
rates_NN
were_VBD [BEMA]
stronger_PRED
against_PIN
the_DT
US_FPP1
dollar_NN
and_CC
the_DT
Japanese_JJ
Yen_NN
by_PIN
four_CD
per_PIN
cent_NN
and_CC
seven_CD
per_PIN
cent_NN
,_,
respectively_RB
,_,
and_ANDC
weaker_JJ
against_PIN
the_DT
Euro_NN
by_PIN
one_CD
per_PIN
cent_NN
,_,
compared_VBN [PASTP]
with_PIN
2001_CD
._.
In_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
performance_NN
,_,
it_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
practice_NN
to_TO
discuss_VB
its_PIT
results_NN
in_PIN
terms_NN
of_PIN
constant_JJ
exchange_NN
rate_NN
CER_NN
growth_NN
._.
This_DEMP
represents_VPRT
growth_NN
calculated_VBN [PRIV]
as_IN
if_COND
the_DT
exchange_NN
rates_NN
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
results_NN
of_PIN
overseas_PLACE
companies_NN
in_PIN
sterling_GER
had_VBD [PEAS]
remained_VBN
unchanged_JJ
from_PIN
those_DEMP
used_VBN
in_PIN
the_DT
previous_JJ
year_NN
._.
The_DT
discussion_NN
in_PIN
this_DEMO
report_NN
is_VPRT [BEMA]
therefore_CONJ
in_PIN
terms_NN
of_PIN
CER_NN
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
%_NN
represents_VPRT
growth_NN
at_PIN
actual_JJ
exchange_NN
rates_NN
._.
CER_CD
%_NN
represents_VPRT
growth_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
._.
During_PIN
2002_CD
FRS_NN
19_CD
Deferred_JJ
tax_NN
has_VPRT [PEAS]
been_VBN [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
._.
This_DEMO
FRS_NN
requires_VPRT [SUAV]
deferred_JJ
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
,_,
rather_CONJ
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
in_PIN
2001_CD
and_CC
earlier_TIME
years_NN
._.
This_DEMO
change_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
prior_JJ
year_NN
adjustment_NOMZ
and_CC
comparative_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
as_RB
necessary_JJ
._.
Cautionary_JJ
statement_NOMZ
regarding_VBG [WZPRES]
forward-looking_JJ
statements_NOMZ
The_DT
Group_NN
's_POS
reports_NN
led_VBD
with_PIN
the_DT
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
SEC_NN
,_,
including_VBG [PRESP]
this_DEMO
document_NOMZ
and_CC
written_VBN [PUBV] [THATD]
information_NOMZ
released_VBN
,_,
or_CC
oral_JJ
statements_NOMZ
made_VBN
,_,
to_PIN
the_DT
public_NN
in_PIN
the_DT
future_NN
by_PIN
or_CC
on_PIN
behalf_NN
of_PIN
the_DT
Group_NN
,_,
may_POMD
contain_VB
forward-looking_JJ
statements_NOMZ
._.
Forward-looking_VBG
statements_NOMZ
give_VPRT
the_DT
Group_NN
's_POS
current_JJ
expectations_NOMZ
or_CC
forecasts_NN
of_PIN
future_JJ
events_NN
._.
An_DT
investor_NN
can_POMD
identify_VB
these_DEMO
statements_NOMZ
by_PIN
the_DT
fact_NN
that_TOBJ
they_TPP3
do_VPRT
not_XX0
relate_VB
strictly_RB
to_PIN
historical_JJ
or_CC
current_JJ
facts_NN
._.
They_TPP3
use_VPRT
words_NN
such_JJ
as_IN
anticipate_VPRT [PRIV]
,_,
estimate_VPRT [PRIV]
,_,
expect_VPRT [PRIV]
,_,
intend_VPRT [SUAV]
,_,
will_PRMD
,_,
project_NN
,_,
plan_NN
,_,
believe_VB [PRIV]
and_CC
other_JJ
words_NN
and_PHC
terms_NN
of_PIN
similar_JJ
meaning_GER
in_PIN
connection_NOMZ
with_PIN
any_QUAN
discussion_NN
of_PIN
future_JJ
operating_GER
or_CC
financial_JJ
performance_NN
._.
In_CONJ
particular_NULL
,_,
these_DEMP
include_VPRT
statements_NOMZ
relating_VBG [WZPRES]
to_PIN
future_JJ
actions_NOMZ
,_,
prospective_JJ
products_NN
or_CC
product_NN
approvals_NN
,_,
future_JJ
performance_NN
or_CC
results_NN
of_PIN
current_JJ
and_PHC
anticipated_JJ
products_NN
,_,
sales_NN
efforts_NN
,_,
expenses_NN
,_,
the_DT
outcome_NN
of_PIN
contingencies_NN
such_JJ
as_IN
legal_JJ
proceedings_GER
,_,
and_ANDC
financial_JJ
results_NN
._.
The_DT
Group_NN
undertakes_VPRT
no_SYNE
obligation_NOMZ
to_TO
update_VB
any_QUAN
forward-looking_JJ
statements_NOMZ
,_,
whether_IN
as_CONJ
a_NULL
result_NULL
of_PIN
new_JJ
information_NOMZ
,_,
future_JJ
events_NN
or_CC
otherwise_CONJ
._.
Forward-looking_VBG
statements_NOMZ
involve_VPRT
inherent_JJ
risks_NN
and_PHC
uncertainties_NN
._.
The_DT
Group_NN
cautions_VPRT
investors_NN
that_TOBJ
a_DT
number_NN
of_PIN
important_JJ
factors_NN
including_VBG [WZPRES]
those_DEMO
in_PIN
this_DEMO
document_NOMZ
could_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
contained_VBN
in_PIN
any_QUAN
forward-looking_JJ
statement_NOMZ
._.
Such_JJ
factors_NN
include_VPRT
,_,
but_CC
are_VPRT [PASS]
not_XX0
limited_VBN
to_TO
,_,
those_DEMP
discussed_VBN
under_IN
Risk_NN
factors_NN
on_PIN
pages_NN
64_CD
and_CC
65_CD
of_PIN
this_DEMO
Annual_JJ
Report_NN
._.
